Cochlear
Exclusive
Funding
The hundreds of millions in tax incentives for Australian start-ups that went south
The R&D tax offset has served as a life raft for some of Australia’s most prominent technology start-ups, though in some cases it wasn’t enough.
- by David Swan
Latest
Opinion
Health
Our track record in medical innovation can only be maintained with funding support
Australian researchers are responsible for a series of globally significant medical inventions and innovations.
- by The Herald's View
Updated
World markets
Healthcare companies, wage data lift ASX after Wall Street gain
The Australian sharemarket climbed on the back of healthcare companies after a set of strong results from some of its biggest players and softer wage data.
- by Millie Muroi
‘Certainly pleased’: Cochlear, CSL count win on multinational tax reporting
Corporate Australia has warned against new tax rules that would require them to share new levels of global tax information publicly.
- by Emma Koehn
Investing in workers critical to solving healthcare squeeze, says Cochlear boss
Cochlear chief executive Dig Howitt says Australia needs training and immigration policies that allow skilled workers to flow into the healthcare sector.
- by Emma Koehn
‘Baseless’: Australian biotech Cochlear steps up fight against US university over hearing device
Hearing implant maker Cochlear will bring a counter claim against the University of Pittsburgh, which has accused the company of infringing on one of its patents with its Nucleus 7 hearing device.
- by Emma Koehn
Cochlear boss urges investment in healthcare workers
Revenues were up at the hearing implants maker but unit volumes in its developed markets dipped as the impact of the Delta and Omicron variants saw operating theatres running below capacity.
- by Emma Koehn
Board games: Is a cosy directors’ club a risk to corporate Australia?
A small group of powerful men, and increasingly women, dominate the boards of Australia’s biggest companies. And some fear the group is too small.
- by Anne Hyland
Rapid testing no substitute to COVID vaccination: Cochlear boss
The $17 billion hearing implants maker has returned to profit, with its boss focused on emerging from the pandemic with a stronger market share. But the Delta variant could threaten its earnings forecast.
- by Emma Koehn
Vaccine ‘not a panacea’ as surgeries bounce back: Cochlear boss
The hearing implant maker is still on the long path back to a COVID normal but can see some light at the end of the tunnel.
- by Emma Koehn
Cochlear boss warns of second wave risks to elective surgery return
The hearing implant maker says the strategy stays the same in tough conditions - but warns of potential disruption from second waves.
- by Emma Koehn
Original URL: https://www.smh.com.au/topic/coh-ej